MAIA Biotechnology has reported positive initial efficacy results from its Phase II THIO-101 trial, Part C, involving its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results